EGFR mutations, including L858R and T790M, are common in NSCLC. TKIs like erlotinib and gefitinib target these mutations but ...

Data from the study suggests that the Rybrevant-Lazcluze combo significantly extends overall survival (“OS”) in NSCLC patients with EGFR exon 19 deletions (ex19del) or exon 21 L858R ...

Rybrevant (amivantamab) has been cleared in combination with chemotherapy for patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R mutations who have previously ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal ...